Literature DB >> 29437554

hsa-mir183/EGR1-mediated regulation of E2F1 is required for CML stem/progenitor cell survival.

Francesca Pellicano1, Laura Park1, Lisa E M Hopcroft1, Mansi M Shah1, Lorna Jackson1, Mary T Scott1, Cassie J Clarke1, Amy Sinclair1, Sheela A Abraham1, Alan Hair1, G Vignir Helgason1, Mark Aspinall-O'Dea2, Ravi Bhatia3, Gustavo Leone4, Kamil R Kranc5, Anthony D Whetton2, Tessa L Holyoake1.   

Abstract

Chronic myeloid leukemia (CML) stem/progenitor cells (SPCs) express a transcriptional program characteristic of proliferation, yet can achieve and maintain quiescence. Understanding the mechanisms by which leukemic SPCs maintain quiescence will help to clarify how they persist during long-term targeted treatment. We have identified a novel BCR-ABL1 protein kinase-dependent pathway mediated by the upregulation of hsa-mir183, the downregulation of its direct target early growth response 1 (EGR1), and, as a consequence, upregulation of E2F1. We show here that inhibition of hsa-mir183 reduced proliferation and impaired colony formation of CML SPCs. Downstream of this, inhibition of E2F1 also reduced proliferation of CML SPCs, leading to p53-mediated apoptosis. In addition, we demonstrate that E2F1 plays a pivotal role in regulating CML SPC proliferation status. Thus, for the first time, we highlight the mechanism of hsa-mir183/EGR1-mediated E2F1 regulation and demonstrate this axis as a novel, critical factor for CML SPC survival, offering new insights into leukemic stem cell eradication.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29437554      PMCID: PMC6027092          DOI: 10.1182/blood-2017-05-783845

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

1.  E2f1-3 are critical for myeloid development.

Authors:  Prashant Trikha; Nidhi Sharma; Rene Opavsky; Andres Reyes; Clarissa Pena; Michael C Ostrowski; Martine F Roussel; Gustavo Leone
Journal:  J Biol Chem       Date:  2010-11-28       Impact factor: 5.157

2.  E2F-1 functions in mice to promote apoptosis and suppress proliferation.

Authors:  S J Field; F Y Tsai; F Kuo; A M Zubiaga; W G Kaelin; D M Livingston; S H Orkin; M E Greenberg
Journal:  Cell       Date:  1996-05-17       Impact factor: 41.582

Review 3.  The regulation of E2F by pRB-family proteins.

Authors:  N Dyson
Journal:  Genes Dev       Date:  1998-08-01       Impact factor: 11.361

4.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Authors:  François-Xavier Mahon; Delphine Réa; Joëlle Guilhot; François Guilhot; Françoise Huguet; Franck Nicolini; Laurence Legros; Aude Charbonnier; Agnès Guerci; Bruno Varet; Gabriel Etienne; Josy Reiffers; Philippe Rousselot
Journal:  Lancet Oncol       Date:  2010-10-19       Impact factor: 41.316

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  The p120-v-Abl protein interacts with E2F-1 and regulates E2F-1 transcriptional activity.

Authors:  M C Birchenall-Roberts; Y D Yoo; D C Bertolette; K H Lee; J M Turley; O S Bang; F W Ruscetti; S J Kim
Journal:  J Biol Chem       Date:  1997-04-04       Impact factor: 5.157

7.  Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation.

Authors:  G Bhardwaj; B Murdoch; D Wu; D P Baker; K P Williams; K Chadwick; L E Ling; F N Karanu; M Bhatia
Journal:  Nat Immunol       Date:  2001-02       Impact factor: 25.606

8.  Role for E2F1 in p210 BCR-ABL downstream regulation of c-myc transcription initiation. Studies in murine myeloid cells.

Authors:  M J Stewart; S Litz-Jackson; G S Burgess; E A Williamson; D S Leibowitz; H S Boswell
Journal:  Leukemia       Date:  1995-09       Impact factor: 11.528

9.  The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells.

Authors:  F Pellicano; P Simara; A Sinclair; G V Helgason; M Copland; S Grant; T L Holyoake
Journal:  Leukemia       Date:  2011-04-12       Impact factor: 11.528

10.  E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells.

Authors:  Jean-Leon Chong; Pamela L Wenzel; M Teresa Sáenz-Robles; Vivek Nair; Antoney Ferrey; John P Hagan; Yorman M Gomez; Nidhi Sharma; Hui-Zi Chen; Madhu Ouseph; Shu-Huei Wang; Prashant Trikha; Brian Culp; Louise Mezache; Douglas J Winton; Owen J Sansom; Danian Chen; Rod Bremner; Paul G Cantalupo; Michael L Robinson; James M Pipas; Gustavo Leone
Journal:  Nature       Date:  2009-12-17       Impact factor: 49.962

View more
  12 in total

1.  Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions.

Authors:  Giovannino Silvestri; Rossana Trotta; Lorenzo Stramucci; Justin J Ellis; Jason G Harb; Paolo Neviani; Shuzhen Wang; Ann-Kathrin Eisfeld; Christopher J Walker; Bin Zhang; Klara Srutova; Carlo Gambacorti-Passerini; Gabriel Pineda; Catriona H M Jamieson; Fabio Stagno; Paolo Vigneri; Georgios Nteliopoulos; Philippa C May; Alistair G Reid; Ramiro Garzon; Denis-Claude Roy; Moutuaata M Moutuou; Martin Guimond; Peter Hokland; Michael W Deininger; Garrett Fitzgerald; Christopher Harman; Francesco Dazzi; Dragana Milojkovic; Jane F Apperley; Guido Marcucci; Jianfei Qi; Katerina Machova Polakova; Ying Zou; Xiaoxuan Fan; Maria R Baer; Bruno Calabretta; Danilo Perrotti
Journal:  Blood Cancer Discov       Date:  2020-07

Review 2.  Chronic myeloid leukemia stem cells.

Authors:  Mohammad Houshmand; Giorgia Simonetti; Paola Circosta; Valentina Gaidano; Alessandro Cignetti; Giovanni Martinelli; Giuseppe Saglio; Robert Peter Gale
Journal:  Leukemia       Date:  2019-05-24       Impact factor: 11.528

Review 3.  Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells.

Authors:  Giovanna Carrà; Antonio Cartellà; Beatrice Maffeo; Alessandro Morotti
Journal:  Blood Lymphat Cancer       Date:  2019-11-06

4.  Inhibition of KPNB1 Inhibits Proliferation and Promotes Apoptosis of Chronic Myeloid Leukemia Cells Through Regulation of E2F1.

Authors:  Teng Wang; Zhenglan Huang; Ningshu Huang; Yuhang Peng; Miao Gao; Xin Wang; Wenli Feng
Journal:  Onco Targets Ther       Date:  2019-12-02       Impact factor: 4.147

Review 5.  Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.

Authors:  Yammy Yung; Emily Lee; Hiu-Tung Chu; Pui-Kwan Yip; Harinder Gill
Journal:  Int J Mol Sci       Date:  2021-01-11       Impact factor: 5.923

6.  Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells.

Authors:  Jérôme Tamburini; Christian Récher; Clément Larrue; Nathan Guiraud; Pierre-Luc Mouchel; Marine Dubois; Thomas Farge; Mathilde Gotanègre; Claudie Bosc; Estelle Saland; Marie-Laure Nicolau-Travers; Marie Sabatier; Nizar Serhan; Ambrine Sahal; Emeline Boet; Sarah Mouche; Quentin Heydt; Nesrine Aroua; Lucille Stuani; Tony Kaoma; Linus Angenendt; Jan-Henrik Mikesch; Christoph Schliemann; François Vergez; Jean-Emmanuel Sarry
Journal:  Nat Commun       Date:  2021-01-18       Impact factor: 14.919

7.  LncRNA Lnc-APUE is Repressed by HNF4α and Promotes G1/S Phase Transition and Tumor Growth by Regulating MiR-20b/E2F1 Axis.

Authors:  Song-Yang Li; Ying Zhu; Ruo-Nan Li; Jia-Hui Huang; Kai You; Yun-Fei Yuan; Shi-Mei Zhuang
Journal:  Adv Sci (Weinh)       Date:  2021-02-01       Impact factor: 16.806

Review 8.  Biological Therapies in the Treatment of Cancer-Update and New Directions.

Authors:  Monika A Papież; Wirginia Krzyściak
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

9.  Modeling and antitumor studies of a modified L-penetratin peptide targeting E2F in lung cancer and prostate cancer.

Authors:  Tazeem Shaik; Gulam M Rather; Nitu Bansal; Tamara Minko; Olga Garbuzenko; Zoltan Szekely; Emine E Abali; Debabrata Banerjee; John E Kerrigan; Kathleen W Scotto; Joseph R Bertino
Journal:  Oncotarget       Date:  2018-09-07

10.  Serine 26 in Early Growth Response-1 Is Critical for Endothelial Proliferation, Migration, and Network Formation.

Authors:  Fernando S Santiago; Yue Li; Levon M Khachigian
Journal:  J Am Heart Assoc       Date:  2021-09-03       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.